BJ Rimel, MD, Discusses Biggest Takeaways from 2021 SGO Annual Meeting

Video

Rimel, of the Cedars-Sinai Medical Center, focused her attention on the main takeaways to come out from the 2021 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

BJ Rimel, MD, of the Cedars-Sinai Medical Center spoke to CancerNetwork® regarding her biggest takeaways when it comes to the data presented at the 2021 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Transcription:

The biggest takeaway for the annual meeting for me is the excitement around seeing the perspectives of clinical trials, innovations in office care, [and] innovations in how we approach getting data from patients or about patients to serve them better. I really thought that was an exciting part of the meeting and I’m looking forward to seeing more of it.

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.